跳至主要内容
临床试验/CTRI/2025/10/096304
CTRI/2025/10/096304尚未招募3 期

A comparative clinical evaluation of amritadi kwath and trivrittadi kwath in the management of vatarakta w.s.r.gout

self sponsered1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2025年11月15日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
120
试验地点
1
主要终点
Relief in symptoms like Pain, redness, swelling, stiffness, Burning in Joints, Reduction in serum uric acid level

研究概览

简要总结

The present clinical study titled “A Comparative Clinical Evaluation of Amritadi Kwatha and Trivrittadi Kwatha in the Management of Vatarakta w.s.r. to Gout” aims to evaluate and compare the therapeutic efficacy of two classical Ayurvedic formulations, Amritadi Kwatha and Trivrittadi Kwatha, in the management of Vatarakta (Gout). Vatarakta is a metabolic disorder correlated with gout in modern medicine, characterized by hyperuricemia and deposition of urate crystals in joints, leading to pain, swelling, and inflammation. This interventional comparative clinical trial will include 120 patients diagnosed with Vatarakta, divided into two groups of 60 each. Group I will receive Amritadi Kwatha 20 ml twice daily, and Group II will receive Trivrittadi Kwatha 20 ml twice daily for 30 days, with follow-ups on the 15th, 30th, and 60th days. The study aims to assess improvement in clinical symptoms and serum uric acid levels to identify an effective, safe, and affordable Ayurvedic management approach for Vatarakta (Gout).

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant Blinded

入排标准

年龄范围
20.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Patients willing to participate in the trial
  • Patients between the age group of 20 years -65 years.
  • Patients having serum uric acid more then 7mg/dl in males and more then 6mg/dl in females with symptoms of Vatrakta.

排除标准

  • Patients who do not consent to participate in the trial.
  • Patients below the age of 20 and above 65 years of age.
  • Patients with asymptomatic hyperuricemia and suffering from Secondary gout.
  • Patients suffering from chronic respiratory, cardiac, hepatic, renal and hormonal disorders
  • Pregnancy and lactating mothers.

结局指标

主要结局

Relief in symptoms like Pain, redness, swelling, stiffness, Burning in Joints, Reduction in serum uric acid level

时间窗: 30 days

次要结局

  • Reduction in the frequency of attack of vatrakta(30 days)

研究者

发起方
self sponsered
申办方类型
Other [self sponsered phd study]
责任方
Principal Investigator
主要研究者

Manju Saini

Guru Ravidas Ayurved University

研究点 (1)

Loading locations...

相似试验

Study on the Role of Amritadi Kwath and Trivrittadi... | 临床试验